Evolent Health's Q4 2025 was characterized by a revenue decline to $468.7 million compared to the prior year, largely impacted by a massive $398 million goodwill impairment charge. Despite the GAAP net loss, the company achieved an Adjusted EBITDA of $37.8 million and provided strong 2026 revenue guidance of $2.4 billion to $2.6 billion, representing approximately 30% growth.

Evolent Health, Inc. reported strong first quarter 2025 results, meeting the high end of their expectations for revenue and reaffirming their full-year 2025 outlook. The company saw significant organic growth with five new revenue agreements and continued to scale its oncology condition management solution, improving member experience and cost outcomes.

Evolent Health delivered fourth quarter and full-year results within outlook, despite elevated oncology costs. The company achieved 100% retention across top customers, representing over 90% of 2024 revenue, and announced two new revenue agreements.

Evolent Health reported a 21.6% increase in revenue to $621.4 million for Q3 2024, driven by strong demand for its complex specialty care solutions and a record six new contract agreements. However, the company experienced a net loss of $(31.2) million, with Adjusted EBITDA negatively impacted by losses in the Performance Suite due to higher paid claims in prior periods and a spike in oncology costs.

Evolent Health reported a 37.9% increase in revenue to $647.1 million compared to the same quarter last year. The company experienced a net loss of $(6.4) million, with an adjusted EBITDA of $52.0 million. Evolent has narrowed its revenue outlook for the full year 2024 and provided updated Adjusted EBITDA guidance, while reiterating confidence in achieving $300 million in Adjusted EBITDA run rate exiting 2024.

Evolent Health reported a 49.6% increase in revenue to $639.7 million for Q1 2024. The company is raising its revenue outlook for the full year 2024 and reiterating its full year Adjusted EBITDA guidance. The net loss attributable to common shareholders was $(25.2) million, with an Adjusted EBITDA of $54.1 million.

Evolent Health announced its Q4 and Full Year 2023 results, with Q4 revenue reaching $556.06 million and a net loss of $41.40 million. The company achieved all financial objectives for the year, driven by underlying growth and the successful integration of NIA. The company is providing initial outlook for 2024 in line with long-term targets.

Evolent Health announced strong Q3 2023 results, with revenue reaching $511.0 million, a 44.9% increase compared to the previous year. The company's specialty care offerings experienced significant growth. Evolent is raising the mid-point of its outlook for revenue and Adjusted EBITDA in 2023.

Evolent Health announced financial results for Q2 2023, featuring a 46.6% increase in revenue to $469.1 million compared to the same period last year. The company reported a net loss attributable to common shareholders of $41.4 million, with an adjusted EBITDA of $47.4 million. Evolent also highlighted new operating partnerships and expansions, raising its Adjusted EBITDA range for 2023.

Evolent Health reported strong first-quarter results with a 44.0% increase in revenue, reaching $427.7 million. The company's total lives on the platform grew significantly, driven by expansion in Performance Suite, Specialty Technology and Services Suite, and Administrative Services. Despite the revenue growth, Evolent Health reported a net loss of $26.3 million, but adjusted EBITDA was $50.5 million.

Evolent Health announced its Q4 2022 results, revealing a 54.0% increase in revenue to $382.4 million compared to the same period last year. However, the company reported a net loss of $11.3 million, with an adjusted EBITDA of $32.3 million.

Evolent Health reported strong Q3 2022 results with a 58.5% increase in revenue to $352.6 million, a net income of $2.1 million, and an adjusted EBITDA of $28.1 million. The company also announced three new operating partnerships and achieved significant sales momentum.

Evolent Health reported a 44.1% increase in revenue to $319.9 million for Q2 2022, with a net loss of $4.6 million and adjusted EBITDA of $21.7 million. The company added 10 new operating partnerships in 2022, exceeding its annual goal. They also closed the acquisition of IPG.

Evolent Health's Q1 2022 revenue reached $297.1 million, a 38.1% increase year-over-year. The company reported a net loss of $5.4 million, but achieved an adjusted EBITDA of $24.3 million. They also added two operating partnerships and announced a client expansion for 2023.

Evolent Health reported GAAP revenue of $248.4 million for Q4 2021, a 0.7% increase year-over-year. The company experienced a net loss of $(5.6) million attributable to common shareholders. Adjusted EBITDA reached $24.3 million.

Evolent Health reported a GAAP revenue of $222.5 million, a 7.1% decrease compared to Q3 2020, but revenue excluding divested assets increased by 36.3%. The company achieved an Adjusted EBITDA of $13.8 million and managed a total of 14.7 million lives. Evolent also announced new agreements with Sunflower Medical Group and Northern Medical Group, along with a partnership with Health New England.

Evolent Health announced its Q2 2021 financial results with a revenue of $222.1 million, a net loss of $(9.1) million, and an adjusted EBITDA of $13.3 million. The company has raised its full-year 2021 guidance. They also entered into an agreement to acquire Vital Decisions and added new provider partnerships.

Evolent Health reported a 29% year-over-year revenue growth excluding revenue from divested assets. The company announced four new partnerships year-to-date and saw strong operational and clinical performance. Adjusted EBITDA margin was 6.9% for Q1 2021, with $15 million in Adjusted EBITDA.

Evolent Health announced its Q4 and full-year 2020 results, revealing a 15.0% increase in GAAP revenue to $271.9 million for the quarter. The company achieved an adjusted EBITDA of $16.1 million, but reported a net loss attributable to common shareholders of $(14.6) million. Evolent also added new regional physician group partners and expanded its partnership with Blue Cross Blue Shield of Texas.

Evolent Health announced its Q3 2020 results, highlighting a 20.2% year-over-year revenue increase to $264.6 million. The company achieved an adjusted EBITDA of $12.7 million and reported a net loss attributable to common shareholders of $(37.3) million. Evolent Health also announced new provider and specialty care customer partnerships.

Evolent Health reported a 25.0% increase in GAAP revenue, reaching $247.3 million, and an Adjusted EBITDA of $3.6 million. The company added two new health plan partners and focused on supporting existing partners during the COVID-19 crisis.

Evolent Health reported a 22.5% increase in GAAP revenue, reaching $236.5 million for the fourth quarter of 2019. The company's net loss attributable to common shareholders was $(198.1) million, which included a non-cash goodwill impairment of $199.8 million. Adjusted EBITDA stood at $8.2 million, and the company had approximately 3.7 million lives on its platform.